GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-  
B6838 N6-CyclopentyladenosineSummary: adenosine A1 receptor agonist -  
B7534 NIDA 41020Summary: CB1 receptor antagonist -  
B1059 MosaprideSummary: Selective 5HT4 agonist -  
B1335 Guanabenz AcetateSummary: α2-adrenergic receptor agonist -  
B6835 CGS 15943Summary: adenosine receptor antagonist -  
B7465 PF 514273Summary: CB1 receptor antagonist -  
B1001 Loxapine1 CitationTarget: 5-HT2 ReceptorsSummary: 5-HT receptor antagonist -  
B1334 DexmedetomidineSummary: α2-adrenergic receptor agonist -  
B7204 Arachidonyl serotoninSummary: Dual FAAH inhibitor/TRPV1 antagonist -  
B6796 MRS 1706Summary: adenosine A2B receptor inverse agonist 
